UA59481C2 - Способ купирования абстинентного синдрома у больных с опийной зависимостью - Google Patents
Способ купирования абстинентного синдрома у больных с опийной зависимостью Download PDFInfo
- Publication number
- UA59481C2 UA59481C2 UA2001074863A UA200174863A UA59481C2 UA 59481 C2 UA59481 C2 UA 59481C2 UA 2001074863 A UA2001074863 A UA 2001074863A UA 200174863 A UA200174863 A UA 200174863A UA 59481 C2 UA59481 C2 UA 59481C2
- Authority
- UA
- Ukraine
- Prior art keywords
- patients
- day
- baclofen
- syndrome
- withdrawal syndrome
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 208000011580 syndromic disease Diseases 0.000 title abstract description 10
- 229940127240 opiate Drugs 0.000 title abstract description 4
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960000794 baclofen Drugs 0.000 claims abstract description 19
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 24
- 206010048010 Withdrawal syndrome Diseases 0.000 claims description 23
- 206010013663 drug dependence Diseases 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 11
- 208000004224 Opium Dependence Diseases 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 abstract description 13
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 13
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 9
- 208000011117 substance-related disease Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229960002069 diamorphine Drugs 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 230000008756 pathogenetic mechanism Effects 0.000 description 3
- 230000003304 psychophysiological effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 241001282135 Poromitra oscitans Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 206010048232 Yawning Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000005040 opiate dependence Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DIDHYKUHZLXCBJ-UHFFFAOYSA-N 2-chloro-2-phenylbutanoic acid Chemical class CCC(Cl)(C(O)=O)C1=CC=CC=C1 DIDHYKUHZLXCBJ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000025551 Lacrimation disease Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- KLISBMUDTJHGSP-AIDJSRAFSA-K magnesium;potassium;(2s)-2-amino-4-hydroxy-4-oxobutanoate;2-amino-4-hydroxy-4-oxobutanoate Chemical compound [Mg+2].[K+].[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)C(N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O KLISBMUDTJHGSP-AIDJSRAFSA-K 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к наркологии, и может использоваться для купирования абстинентного синдрома у больных с опийной зависимостью. Изобретение состоит в том, что в дополнение к традиционной терапии вводят баклофен на протяжении 10 дней с постепенным увеличением суточной дозы с 25,0 мг до 175,0 мг. Затем дозу постепенно снижают до 25,0 мг. Кроме того, внутривенно вводят 10% раствор хлорида кальция в дозе 10 мл на протяжении 10 дней.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2001074863A UA59481C2 (ru) | 2001-07-11 | 2001-07-11 | Способ купирования абстинентного синдрома у больных с опийной зависимостью |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2001074863A UA59481C2 (ru) | 2001-07-11 | 2001-07-11 | Способ купирования абстинентного синдрома у больных с опийной зависимостью |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA59481C2 true UA59481C2 (ru) | 2003-09-15 |
Family
ID=74220210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001074863A UA59481C2 (ru) | 2001-07-11 | 2001-07-11 | Способ купирования абстинентного синдрома у больных с опийной зависимостью |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA59481C2 (ru) |
-
2001
- 2001-07-11 UA UA2001074863A patent/UA59481C2/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailey et al. | Anesthetic induction with fentanyl | |
| Osgood et al. | Management of burn pain in children | |
| Khanna et al. | Comparative evaluation of bupivacaine plain versus bupivacaine with fentanyl in spinal anaesthesia in geriatric patients | |
| Camp | Paralysis agitans and multiple sclerosis and their treatment. | |
| RU2322985C2 (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| DE69634662T2 (de) | Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester | |
| EP2138174A1 (en) | Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management | |
| Porter | A review of intrathecal baclofen in the management of spasticity | |
| US20060084659A1 (en) | Augmentation of psychotherapy with cannabinoid reuptake inhibitors | |
| KR102693607B1 (ko) | 하지 불안 증후군을 치료하기 위한 치료제 | |
| RU2104006C1 (ru) | Способ лечения наркомании | |
| JP3916563B2 (ja) | Ｐ物質の投与を含む治療方法 | |
| MAY et al. | Dormison, a new type of hypnotic: its therapeutic use in psychiatric patients | |
| UA59481C2 (ru) | Способ купирования абстинентного синдрома у больных с опийной зависимостью | |
| RU2362580C1 (ru) | Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы | |
| SU1734754A1 (ru) | Ноотропное средство | |
| D'Souza et al. | Side effects of opioid analgesics and narcotic antagonists | |
| Weiss | The clinical use and dangers of hypnotics | |
| JP2008536921A (ja) | アルコール及び／又は刺激物質の乱用を治療するための選択的塩素イオンチャネルモジュレーターの使用 | |
| Biziere et al. | Living with Parkinson's disease | |
| Phero | Pharmacotherapy for chronic facial pain | |
| Ewing | The First Phase of Alcoholic Rehabilitation. Report of a Controlled Study with Benactyzine, Paraldehyde and Pyridoxine | |
| Akki et al. | To evaluate the Comparative efficacy of Svalpamasha Taila Nasya and Parinata Keriksheeradi Nasya in Avabahuka (Frozen shoulder) | |
| RU2197284C1 (ru) | Способ лечения алкогольной зависимости | |
| WO2009027564A1 (es) | Uso y métodos de uso de un antagonista del receptor (5-ht3) de la serotonina3 y un modulador selectivo de los canales de cloruro para el tratamiento de la adicción a o la dependencia de fármacos/drogas o trastornos del sistema nervioso central |